City Therapeutics doses first participant in Phase 1 trial of CITY-RBP4 for Stargardt disease
CTY•City Therapeutics dosed the first participant in its Phase 1 trial of CITY-RBP4, its second program to enter clinical testing. Initial results are expected in mid-2027.
1. Trial begins
The study will evaluate safety, tolerability and biological activity in healthy volunteers and patients. CITY-RBP4 is an RNAi candidate intended to reduce vitamin A delivery to the eye; a planned extension study will assess long-term safety and preliminary efficacy.
